Mazdutide, Innovent Biologics’ GLP-1/glucagon agonist, hits 15% weight loss in 24 weeks (Obesity, 2023), in Phase III in China as of March 2025—possible 2025 approval there. At auravi, Bone Support and Antioxidant Defense power your Mazdutide journey. Let’s unpack what it is, its pros and cons, how it differs, and how our products support it, with science as our contender.
What Is Mazdutide?
Mazdutide is a weekly injectable dual GLP-1/glucagon agonist in Phase III (China), targeting obesity and diabetes. GLP-1 curbs appetite, glucagon boosts fat burn (Diabetes Care, 2023). Phase II hit 15% loss—competitive with Ozempic—aiming for global rollout post-2025.
Pros of Mazdutide
- Weight Loss: 15% in 24 weeks—strong showing (Obesity, 2023).
- Dual Action: GLP-1/glucagon ramps fat burn (Journal of Clinical Endocrinology & Metabolism, 2023).
- Weekly: One shot—easy (Clinical Pharmacokinetics, 2023).
- Metabolic Edge: Enhances fat oxidation—potential diabetes perk.
Cons and Possible Side Effects
- GI Distress: 45% nausea, 30% constipation—dual hit (Obesity, 2023).
- Muscle Loss: 25-30% lean mass risk (Obesity, 2020).
- Fatigue: 25% report energy dips—calorie loss.
- Early Stage: Phase III—global data pending.
How Mazdutide Differs from Current GLP-1s
Unlike Ozempic (14.9%, GLP-1 only, Lancet, 2021), Mazdutide’s glucagon adds fat burn—15% matches but with a twist.
Compared to Mounjaro (20.9%, GLP-1/GIP, New England Journal of Medicine, 2022), it swaps GIP for glucagon—similar loss, different metabolic focus.
Versus Wegovy (17.4%, JAMA, 2021), Mazdutide’s dual action offers a unique edge.
auravi’s Support for Your Mazdutide Journey
Mazdutide contends—our products strengthen:
- Bone Support: Protects bones from rapid loss (Osteoporosis International, 2019).
- Antioxidant Defense: 600 mg NAC supports fat metabolism (Free Radical Biology & Medicine, 2018).
Add Gut Balance for GI ease.
Contend and Win
Mazdutide’s a contender—win with Bone Support. Shop now at auravi and conquer!
